Business Economy

Blood Group Typing Market Size, Regional Demand, Trends and Forecast to 2024-2032

Mr Accuracyreports has published a new research report titled “

Blood Group Typing Market By Product (Consumables, Instruments, Services), By Test Type (ABO, Antigen, Antibody, HLA), By Technique (Assay-Based, PCR, Microarray, Massively Parallel Sequencing), By End-User (Hospital, Blood Banks), & Region For 2024-2031

” in its research database. Get a Free Sample PDF of this Research Report for more Insights with Table of Content, Research Methodology, and Graphs –

https://www.mraccuracyreports.com/request/download/5/856581/Blood-Group-Typing-Market

The primary purpose of this market research is to understand customer needs, preferences, and behaviors. By analyzing this data, businesses can develop effective marketing strategies, improve products or services, and enhance customer satisfaction. Additionally, current market research 2024 helps identify market trends, assess the competitive landscape, and evaluate the potential for new products or servicesBrowse Complete Report Here-

https://www.mraccuracyreports.com/marketreports/5/856581/Blood-Group-Typing-Market

Blood Group Typing Market Valuation – 2024-2031

Increasing demand for safe blood transfusions and organ transplants. As the world’s population grows and ages, the number of operations, trauma cases, and chronic diseases that require blood transfusions and transplants are increasing. This has heightened the importance of proper blood group typing to assure compatibility and avoid unwanted reactions is propelling the market growth surpassing USD 2.96 Billion in 2023 and reaching USD 6.16 Billion by 2031.

Furthermore, advances in medical technology and diagnostics, together with increased awareness of the value of blood typing in prenatal testing and illness management, are driving the industry forward. These advancements increase the accuracy and efficiency of blood group typing, making it more accessible and dependable is expected to grow at a CAGR of about 9.60% from 2024 to 2031.

Blood Group Typing Market: Definition/ Overview

Blood group typing is the technique of determining an individual’s blood type by examining the presence or absence of particular antigens on the surface of red blood cells. This method is critical for a variety of medical purposes, including verifying compatibility for blood transfusions and organ transplants, as well as managing pregnancies to prevent infant hemolytic syndrome. It is also essential for forensic science and research. The future of blood group typing seems hopeful, because to advances in genetic testing and molecular diagnostics, which improve accuracy and speed. As healthcare systems throughout the world prioritize patient safety and tailored therapy, the demand for accurate and efficient blood group typing is likely to rise, enabling more medical and healthcare applications.

What’s inside a
industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will Increasing Demand for Safe Blood Transfusion and Organ Transplants Drive the Blood Group Typing Market?

The rising demand for safe blood transfusions and organ transplants will drive the Blood Group Typing Market. Precision blood group typing is essential for guaranteeing compatibility between donors and recipients, which is vital for avoiding adverse responses and ensuring the success of these medical treatments.

The expanding global population and aging demographics contribute to an increase in operations, chronic diseases, and trauma cases requiring blood transfusions and organ transplants. As these medical treatments become more widespread, there is a greater demand for accurate blood group typing. To minimize severe immunological reactions and difficulties, hospitals and medical facilities must ensure that the blood and organs used in transfusions and transplants match the recipients’ blood types.

Advances in medical technology and diagnostics are improving blood group typing systems’ efficiency and accuracy. Blood typing is becoming faster, more reliable, and more accessible because to innovations like automated blood type equipment, molecular genotyping, and sophisticated serological techniques. These technical developments not only increase the safety of transfusions and transplants, but they also enable large-scale screening and matching processes, thereby driving the industry even higher.

Increasing awareness and severe regulatory standards for blood safety are encouraging healthcare practitioners to use more precise and extensive blood typing techniques. Governments and health organizations around the world are highlighting the importance of safe transfusion practices in reducing the risk of transfusion-transmitted diseases and consequences. The rising emphasis on safety and quality in healthcare is driving demand for reliable blood group typing systems and solutions.

The increasing use of personalized medicine and targeted therapeutics emphasizes the need of correct blood group typing. In customized medicine, therapies and medical decisions are tailored to each patient’s unique traits, including blood type. Accurate blood group typing is critical in this setting to ensure that patients receive the most effective and safe medications. As customized medicine evolves and expands, the demand for exact blood group typing will increase, propelling the market into the future.

Will Rising High Cost of Advanced Technologies and Equipment Hinder the Growth of the Blood Group Typing Market?

The rising high cost of innovative technologies and equipment may impede the expansion of the blood group typing industry. The initial cost of obtaining and maintaining modern blood typing machines and systems is significant, making it difficult for smaller healthcare facilities and universities in underdeveloped countries to purchase these technology. This financial barrier prevents widespread use of advanced blood group typing procedures, limiting market growth in areas where such breakthroughs are most required.

The high expense of sophisticated blood typing technology, such as automated analyzers and molecular genotyping platforms, presents a considerable challenge. These cutting-edge systems are extremely accurate and efficient, but they come at a great cost. Smaller clinics, hospitals, and blood banks may struggle to justify these costs, choosing instead for less expensive, but less precise and slower manual procedures. This financial limitation may cause delays in the introduction of advanced blood typing solutions, delaying market growth.

The operating and maintenance costs of modern blood group typing equipment intensify the financial burden. These systems frequently necessitate specific chemicals, regular calibration, and professional operators to function and maintain successfully. The recurring costs for consumables, maintenance contracts, and training programs add to the overall cost, making it challenging for healthcare providers with restricted budgets to keep using these technologies. As a result, market growth may be hampered since companies are hesitant to invest in or continue employing expensive blood typing equipment.

The cost issue is particularly acute in developing nations, where healthcare budgets are frequently constrained. In these places, the emphasis is usually on meeting more immediate healthcare needs, and investments in advanced diagnostic tools may be overlooked. The cost issue is especially acute in developing nations, where healthcare expenditures are frequently constrained. In these places, the emphasis is often on meeting immediate healthcare requirements, and investments in advanced diagnostic tools may be overlooked. As a result, the adoption of advanced blood group typing technology is delayed, and the market potential remains untapped. The gap in technological adoption between developed and developing nations poses a substantial impediment to the global expansion of the Blood Group Typing Market.

The difficulties associated with unusual blood types, as well as the demand for highly accurate and trustworthy testing procedures, provide substantial hurdles to the blood group typing industry. Precision identification of rare blood types necessitates modern technology and knowledge, which are both technically hard and resource-intensive. This can result in increasing expenses and operational challenges, especially for smaller facilities and those in resource-constrained areas. As a result, these limitations impede widespread adoption and deployment of advanced blood typing technologies, consequently hurting market growth.

Furthermore, a lack of experienced individuals to execute and interpret blood group typing tests complicates the business. A lack of skilled specialists can result in errors and inefficiencies in blood typing, reducing the dependability of results. This scarcity makes it difficult for healthcare facilities to properly integrate modern blood typing technologies, thereby restricting market growth and widespread adoption.

Category-Wise Acumens

Will Rising Demand for ABO Blood Typing Test Drive the Blood Group Typing Market?

The rising frequency of chronic diseases, combined with an increase in the number of surgical procedures, has resulted in a greater demand for blood transfusion. Accurate blood typing is critical for guaranteeing compatibility between donors and recipients, which reduces the chance of adverse responses during various medical procedures. As a result, demand for the ABO blood typing test has surged dramatically, propelling the industry forward.

The growing healthcare infrastructure and facilities in emerging markets have also contributed to the rising use of advanced blood type technologies, such as ABO testing. These facilities require dependable and effective blood typing systems to fulfill the needs of a bigger patient population. The extensive usage of the ABO blood typing test in blood banks and healthcare settings ensures compatibility and patient safety, which drives market growth.

Advances in medical technology and diagnostic instruments have improved the accuracy and efficiency of blood typing systems. The capacity to quickly and accurately detect blood groups using automated methods has raised demand for the ABO blood typing test, as healthcare professionals place a premium on patient safety and medical procedure reliability.

For Instance, in February 2024, Anbio Biotechnology (“Anbio”), a leading global diagnostic device and assay company, announced that they exhibit the ABO & Rhd Blood Grouping Kit, a qualitative detection test kit for the ABO and D antigens of the Rhd blood group system on human red blood cells in whole blood or 10% red cell suspensions in physiological saline, at Medlab Middle East 2024 in Dubai. Anbio’s ABO & Rhd Blood Grouping Kit uses the Dot-filtration technology to obtain precise results from fresh fingertip blood in as little as 1 minute. It has a storage life of 24 months and does not require additional refrigeration or cold-chain shipping. Medlab ME will be Anbio’s first international display with the ABO & Rhd Blood Grouping Kit.

Meanwhile, the “HLA” (Human Leukocyte Antigen) typing test is the fastest growing area, owing to increased demand for organ transplants and advances in immunogenetics. HLA typing is critical for transplant matching since it helps assess donor-recipient compatibility, lowering the risk of transplant rejection and increasing the procedure’s success rates. With a rising emphasis on personalized medicine and better patient outcomes, HLA typing has become increasingly significant, leading to the segment’s rapid expansion.

Will Rising Adoption of Blood Groping Typing Market Techniques Drive the Blood Group Typing Market?

The increasing usage of improved blood grouping typing techniques will undoubtedly drive the Blood Group Typing Market. Medical technological improvements have resulted in the development of sophisticated blood grouping typing procedures including as assay-based approaches, polymerase chain reaction (PCR), microarrays, and massively parallel sequencing. These techniques provide greater accuracy, faster findings, and more extensive genetic information, which is critical for guaranteeing patient safety during transfusions and transplants. As healthcare institutions continue to invest in these advanced technologies, their acceptance rate is likely to rise, propelling overall market growth.

There is an increasing emphasis on patient safety and individualized care. Blood group typing is critical to guaranteeing compatibility and reducing the risk of adverse responses during transfusions and transplants. The use of modern technology such as microarrays and massively parallel sequencing allows healthcare professionals to give more specialized and accurate treatment plans, which promotes the growth of personalized medicine practices. This increased emphasis on tailored healthcare solutions adds to the growing demand for sophisticated blood typing techniques.

The growing healthcare infrastructure and quantity of medical facilities worldwide creates a greater demand for accurate blood group typing technologies. Healthcare professionals are focusing on reliable diagnostic tools to improve patient outcomes and medical procedures. The use of sophisticated procedures enables efficient and reliable blood group typing, which boosts market growth.

Also, high awareness of the importance of blood group typing in medical practices, as well as the increased prevalence of chronic diseases and surgical operations, have accelerated the use of modern technology. The expanding patient population and the need for precise diagnosis and treatment choices are increasing the demand for dependable and effective blood typing procedures, boosting the overall growth of the Blood Group Typing Market.

On the other hand, “Massively Parallel Sequencing” is the market’s fastest-growing segment. This new method provides high-resolution, comprehensive blood typing and HLA typing capabilities, which are motivated by its use in customized medicine and capacity to deliver detailed genetic information with increased accuracy. As these new procedures evolve and become more generally accepted, they will help to drive the Blood Group Typing Market forward.

Gain Access into Blood Group Typing Market Report Methodology

Country/Region-wise

Will Rising Advanced Healthcare Infrastructure in North America Drive the Blood Group Typing Market?

The growth of advanced healthcare infrastructure, such as sophisticated medical facilities and blood banks, has contributed to increased need for precise and dependable blood group typing technologies. Healthcare providers in North America are increasingly using modern diagnostic methods to verify blood compatibility during transfusions and organ transplantations. The availability of cutting-edge medical facilities and the use of cutting-edge technology have resulted in a higher emphasis on precision and accuracy in blood typing, which has accelerated market expansion.

The emphasis on personalized medicine in North America, which tailors treatment to unique patient characteristics, has boosted demand for precise and thorough blood typing. Personalized medicine necessitates accurate blood type identification in order to provide the most appropriate and successful treatment alternatives. This increased emphasis on personalized healthcare practices encourages the use of sophisticated blood typing procedures and technologies, supporting the market’s expansion.

The rising prevalence of chronic diseases, combined with North America’s aging population, has led to an increase in surgical procedures, blood transfusions, and organ transplants. These medical procedures necessitate precise blood group typing to ensure donor-recipient compatibility and reduce the risk of adverse responses. As a result, there is an increasing demand for enhanced blood typing technologies that produce efficient and precise results, propelling the market forward.

North America’s healthcare regulatory environment is well-established, with an emphasis on patient safety and medical care quality. This regulatory framework promotes healthcare practitioners to use advanced blood group typing technology that give greater accuracy and dependability. The strict adherence to these laws also increases the demand for innovative diagnostic instruments and procedures, hence promoting overall market growth.

Will Increasing Awareness of Blood Safety in Asia-Pacific Propel the Blood Group Typing Market?

The increasing awareness of blood safety in the Asia-Pacific region would surely drive the Blood Group Typing Market. Several reasons contribute to this trend, including expanding healthcare infrastructure, rising healthcare costs, and an increase in the number of blood transfusions and organ transplants.

The expansion of healthcare infrastructure and services in Asia-Pacific, particularly the creation of advanced medical facilities and blood banks, has had a significant impact on the expanding demand for precise blood typing. As healthcare systems become more comprehensive and accessible, there is an increasing emphasis on blood safety to avoid complications during transfusions and transplants. As a result, the demand for precise blood group typing technologies and procedures is growing, propelling the market ahead.

The increasing awareness of blood safety among healthcare professionals and people is impacting the use of improved blood typing technology. The growing emphasis on avoiding transfusion-transmitted illnesses and adverse responses has resulted in greater investment in blood group typing systems with improved accuracy and reliability. This rising knowledge pushes healthcare professionals to use advanced and automated blood typing systems, which drives up demand for these technologies.

The growing number of surgeries, trauma cases, and chronic diseases in the Asia-Pacific area, particularly in India and China, has resulted in an increase in blood transfusions and organ transplantation. These medical treatments demand exact blood group identification to assure donor-recipient compatibility. As a result, the increasing demand for blood group typing has been a driving force in market expansion.

Government initiatives and laws aimed at improving healthcare standards and promoting blood safety are also driving market growth. As Asia-Pacific countries engage in healthcare infrastructure and develop blood safety rules, there is a strong drive to use modern blood group typing technologies to maintain high standards in medical procedures. These measures not only contribute to overall market growth, but also urge healthcare providers to emphasize blood safety, hence increasing demand for sophisticated blood typing procedures.

Competitive Landscape

The competitive landscape of the Blood Group Typing Market features a variety of players, including diagnostic and medical device companies, research institutions, and healthcare providers. These entities contribute to the development and distribution of innovative blood typing technologies and solutions. Additionally, there are emerging players focusing on niche segments, such as molecular diagnostics and genetic testing, which offer specialized and advanced blood typing methodologies. The market is also characterized by collaborations and partnerships between established players and research institutions, fostering innovation and the advancement of blood typing techniques. Moreover, the growing emphasis on personalized medicine and patient safety has led to increased investments in research and development, driving market expansion.

Some of the prominent players operating in the Blood Group Typing Market include:

Abbott Laboratories, Bio-Rad Laboratories, Inc., Hoffmann-La Roche Ltd., Grifols,, Immucor, Inc., Ortho Clinical Diagnostics, Quotient Limited, BioMérieux SA, DiaSorin S.p.A., and Merck KGaA.

Latest Developments

  • In January 2024, A Chinese hospital discovered a new genetic pattern for the rare blood type P. The frequency of type p blood in China is less than one in a million. According to the US-based GenBank sequence database, the nucleotide sequence found in the sample is unique.
  • In May 15, Thermo Fisher Scientific Inc., a global leader in science, has launched the Applied Biosystems™ Axiom™ BloodGenomiX™ Array* and Software. This innovative solution enables more precise blood genotyping for clinical research. The novel array detects the majority of extended and rare blood groups, tissue (HLA), and platelet (HPA) types in a single high-throughput experiment, paving the way for future advances in donor blood matching for extended phenotypes.

Report Scope

REPORT ATTRIBUTES DETAILS
Study Period

2018-2031

Growth Rate

CAGR of ~9.60% from 2024 to 2031

Base Year for Valuation

2023

Historical Period

2018-2022

Forecast Period

2024-2031

Quantitative Units

Value in USD Billion

Report Coverage

Historical and Forecast Revenue Forecast, Historical and Forecast Volume, Growth Factors, Trends, Competitive Landscape, Key Players, Segmentation Analysis

Segments Covered
  • Product
  • Test Type
  • Technique
  • End-User
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Key Players

Abbott Laboratories, Bio-Rad Laboratories, Inc., Hoffmann-La Roche Ltd., Grifols,, Immucor, Inc., Ortho Clinical Diagnostics, Quotient Limited.

Customization

Report customization along with purchase available upon request

Blood Group Typing Market, By Category

Product:

  • Consumables
  • Instruments
  • Services

Test Type:

  • ABO
  • Antigen
  • Antibody
  • HLA

Technique:

  • Assay-based
  • PCR
  • Microarray
  • Massively Parallel Sequencing

End-User:

  • Hospital
  • Blood Banks

Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

Research Methodology of Market Research: